HK1051324A1 - Methods and compositions for modulating alpha adrenergic receptor activity. - Google Patents
Methods and compositions for modulating alpha adrenergic receptor activity.Info
- Publication number
- HK1051324A1 HK1051324A1 HK03103605A HK03103605A HK1051324A1 HK 1051324 A1 HK1051324 A1 HK 1051324A1 HK 03103605 A HK03103605 A HK 03103605A HK 03103605 A HK03103605 A HK 03103605A HK 1051324 A1 HK1051324 A1 HK 1051324A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- compositions
- adrenergic receptor
- receptor activity
- alpha adrenergic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/548,410 US6313172B1 (en) | 2000-04-13 | 2000-04-13 | Methods and compositions for modulating alpha adrenergic receptor activity |
PCT/US2001/011843 WO2001078703A2 (en) | 2000-04-13 | 2001-04-11 | Methods and compositions for modulating alpha adrenergic receptor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1051324A1 true HK1051324A1 (en) | 2003-08-01 |
Family
ID=24188743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03103605A HK1051324A1 (en) | 2000-04-13 | 2003-05-21 | Methods and compositions for modulating alpha adrenergic receptor activity. |
Country Status (12)
Country | Link |
---|---|
US (1) | US6313172B1 (es) |
EP (1) | EP1280525B1 (es) |
JP (1) | JP2003530430A (es) |
AT (1) | ATE288747T1 (es) |
AU (2) | AU5338401A (es) |
CA (1) | CA2406057C (es) |
DE (1) | DE60108857T2 (es) |
ES (1) | ES2233627T3 (es) |
HK (1) | HK1051324A1 (es) |
NZ (1) | NZ522027A (es) |
TW (1) | TWI299662B (es) |
WO (1) | WO2001078703A2 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030199574A1 (en) | 2000-03-02 | 2003-10-23 | Vitreo-Retinal Technologies, Inc. | Treatment of ophthalmic disorders using urea and urea derivatives |
US7335803B2 (en) | 2001-10-19 | 2008-02-26 | Allergan, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
US6534542B2 (en) * | 2001-02-27 | 2003-03-18 | Allergen Sales, Inc. | (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors |
IL162269A0 (en) | 2001-12-05 | 2005-11-20 | Baylor College Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
CA2475338C (en) * | 2002-02-13 | 2014-08-19 | Vitreo-Retinal Technologies, Inc. | Treatment of ophthalmic disorders using urea and urea derivatives |
US7323485B2 (en) | 2002-05-21 | 2008-01-29 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7276522B2 (en) * | 2002-05-21 | 2007-10-02 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7345065B2 (en) * | 2002-05-21 | 2008-03-18 | Allergan, Inc. | Methods and compositions for alleviating pain |
US7091232B2 (en) * | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
US7358269B2 (en) * | 2002-05-21 | 2008-04-15 | Allergan, Inc. | 2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one |
AU2003259846A1 (en) * | 2002-08-16 | 2004-03-03 | The General Hospital Corporation | Non-invasive functional imaging of peripheral nervous system activation in humans and animals |
PL376347A1 (en) * | 2002-10-08 | 2005-12-27 | Allergan, Inc. | Method of using (2-imidazolin-2-ylamino) qinoxalines in the treatment of dementia and parkinsons |
NZ539328A (en) * | 2002-10-08 | 2007-01-26 | Allergan Inc | Use of alpha 2B or 2B/2C adrenoceptor agonists for the treatment of Alzheimer's or Parkinson's disease |
US20050059664A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
US20060293359A1 (en) * | 2003-06-25 | 2006-12-28 | Allergan, Inc. | Methods and compositions for the treatment of diabetes |
MXPA06013133A (es) | 2004-05-11 | 2007-05-23 | Emotional Brain Bv | Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina. |
CA2581828A1 (en) | 2004-09-24 | 2006-04-06 | Allergan, Inc. | 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
BRPI0613077A2 (pt) * | 2005-06-29 | 2010-12-21 | Allergan Inc | agonistas alfa-2 andrenérgicos para o tratamento de dor |
US7390829B2 (en) * | 2005-06-29 | 2008-06-24 | Allergan, Inc. | Alpha-2 adrenergic agonists |
EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
CN114073696A (zh) * | 2010-08-16 | 2022-02-22 | 阿勒根公司 | 用α-2B肾上腺素能受体激动剂活化调节T细胞的方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3562391A (en) * | 1969-06-17 | 1971-02-09 | American Cyanamid Co | Method of suppressing inflammation in mammals |
SU795462A3 (ru) | 1975-03-14 | 1981-01-07 | Эдьт Дьедьесерведьесети Дьяр (Фирма) | Способ получени тиокарбамидныхпРОизВОдНыХ |
US4460602A (en) * | 1981-06-30 | 1984-07-17 | The Procter & Gamble Company | Urea derivatives |
GB8715357D0 (en) * | 1987-06-30 | 1987-08-05 | Sandoz Inst For Medical Resear | Organic compounds |
US4988688A (en) * | 1989-08-02 | 1991-01-29 | Warner-Lambert Company | 4-(N-substituted amino)-2-butynyl-1-ureas and thioureas and derivatives thereof as centrally acting muscarinic agents |
HU210683B (en) * | 1990-06-18 | 1995-06-28 | Sandoz Ag | Process for producing n-benzyl-n1-(phenyl-alkyl)-thiourea derivatives and pharmaceutical compositions containing the same |
US5212176A (en) | 1990-06-29 | 1993-05-18 | Abbott Laboratories | R(+)-terazosin |
US6545182B2 (en) * | 2000-04-13 | 2003-04-08 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
-
2000
- 2000-04-13 US US09/548,410 patent/US6313172B1/en not_active Expired - Fee Related
-
2001
- 2001-04-11 AU AU5338401A patent/AU5338401A/xx active Pending
- 2001-04-11 EP EP01926876A patent/EP1280525B1/en not_active Expired - Lifetime
- 2001-04-11 WO PCT/US2001/011843 patent/WO2001078703A2/en active IP Right Grant
- 2001-04-11 CA CA002406057A patent/CA2406057C/en not_active Expired - Fee Related
- 2001-04-11 NZ NZ522027A patent/NZ522027A/en unknown
- 2001-04-11 AT AT01926876T patent/ATE288747T1/de not_active IP Right Cessation
- 2001-04-11 DE DE60108857T patent/DE60108857T2/de not_active Expired - Lifetime
- 2001-04-11 JP JP2001576004A patent/JP2003530430A/ja active Pending
- 2001-04-11 AU AU2001253384A patent/AU2001253384B2/en not_active Ceased
- 2001-04-11 ES ES01926876T patent/ES2233627T3/es not_active Expired - Lifetime
- 2001-04-13 TW TW090108915A patent/TWI299662B/zh not_active IP Right Cessation
-
2003
- 2003-05-21 HK HK03103605A patent/HK1051324A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US6313172B1 (en) | 2001-11-06 |
TWI299662B (en) | 2008-08-11 |
WO2001078703A2 (en) | 2001-10-25 |
AU5338401A (en) | 2001-10-30 |
EP1280525B1 (en) | 2005-02-09 |
DE60108857D1 (de) | 2005-03-17 |
AU2001253384B2 (en) | 2006-02-02 |
CA2406057A1 (en) | 2001-10-25 |
EP1280525A2 (en) | 2003-02-05 |
NZ522027A (en) | 2004-11-26 |
DE60108857T2 (de) | 2005-12-29 |
WO2001078703A3 (en) | 2002-03-21 |
CA2406057C (en) | 2009-08-04 |
JP2003530430A (ja) | 2003-10-14 |
ES2233627T3 (es) | 2005-06-16 |
ATE288747T1 (de) | 2005-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1051005A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
AU5338401A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
IL144948A0 (en) | Electroactive pore | |
AU5624699A (en) | Use of 5ht-6 antagonists | |
GB2352395A (en) | Paroxetine methanesulfonate | |
AP2004002982A0 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain. | |
MY140767A (en) | Compounds, methods and compositions | |
EP1404863A4 (en) | PIBS AS P53 PATH MODIFICATORS AND USE METHOD | |
MY151032A (en) | Treatment of tnf? related disorders | |
BR0309278A (pt) | Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto | |
AU5186799A (en) | Peptides of il-2 and derivatives thereof and their use as therapeutic agents | |
AU2001253384A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
TR199902449T2 (xx) | Farmakolojik etkin maddeler. | |
SE9802208D0 (sv) | Novel compounds | |
MY137620A (en) | Therapeutic treatment | |
TR200101149T2 (tr) | Dış retina bozukluklarının tedavisi. | |
BG105962A (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
SE9802209D0 (sv) | Novel compounds | |
MX2007004461A (es) | Composiciones farmaceuticas a base de antagonistas de nk2 para uso pediatrico. | |
CA2416879A1 (en) | Methods of treating cancer and the pain associated therewith using endothelin antagonists | |
WO2002024181A3 (en) | The use of melatonin for induction of general anesthesia | |
AU2002347984A1 (en) | Use of norepinephrine reuptake inhibitors for the treatment of tic disorders | |
UA32314A (uk) | Спосіб лікування некротичного панкреатиту | |
UA32315A (uk) | Спосіб накладання шкірного шва |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20110411 |